Xiangxue Pharmaceutical (300147.SZ): XLS-103 injection obtained approval for clinical trials of the drug.

18:40 23/12/2025

ST Xiangxue (300147.SZ) announced that its subsidiary Xiangxue Life Science and Technology (Guangdong) Co., Ltd. (hereinafter referred to as "Xiangxue Life Science") has received two drug clinical trial approval notices issued by the National Medical Products Administration (NMPA) (Notice numbers: 2025LP03514, 2025LP03515). Xiangxue Life Science's XLS-103 injection new drug clinical registration application has obtained clinical trial approval.

Xiangxue Pharmaceutical (300147.SZ) announced that its subsidiary, Xiangxue Life Science Technology (Guangdong) Co., Ltd. (referred to as "Xiangxue Life Science"), has received two "Drug Clinical Trial Approval Notices" (notice numbers: 2025LP03514, 2025LP03515) issued by the National Medical Products Administration. Xiangxue Life Science's new drug clinical registration application for XLS-103 injection has obtained clinical trial approval. This approval for the XLS-103 injection to undergo clinical trials marks the sixth and seventh "Clinical Trial Approval Notices" for TCR-T products that Xiangxue Life Science has received based on its existing TCR T cell therapy core technology and research and development platform.

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"

Software crashed together? Roblox (RBLX.US): It has an ecological closed-loop, Genie can't break.

Industrial: Hong Kong stock market sentiment index has reached the bottom area.

"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"